vernakalant
Sign in to saveAlso known as RSD1235, (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol
Vernakalant, sold under the brand name Brinavess, is a class III antiarrhythmic drug for the acute conversion of atrial fibrillation, in form of an intravenous infusion. It has been approved for use in the European Union and the United Kingdom since 2010. The US Food and Drug Administration denied approval in 2008 and 2019.
~7 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics and pharmacogenomics
- Chemistry
- History
- References
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 446573380 | IUPAC_name = (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidin-3-ol | image = Vernakalant.svg | image_class = skin-invert-image | alt =
| tradename = Brinavess | pregnancy_AU = | pregnancy_category = | routes_of_administration = Intravenous, | ATC_prefix = C01 | ATC_suffix = BG11
Excerpted from Wikipedia’s “vernakalant” article, available under the CC BY-SA 4.0 licence.